Skip to main content
Premium Trial:

Request an Annual Quote

Roka Bioscience Q3 Revenues Up 27 Percent

NEW YORK (GenomeWeb) – Roka Bioscience reported after the close of the market Monday a nearly 27 percent increase in its third quarter revenues due to increased sales of its Atlas molecular pathogen detection instruments. 

For the three-month period ended Sept. 30, Roka's revenues rose to $1.9 million from $1.5 million in the same period the year before. The company attributed the revenue growth to an increased number of Atlas placements and increased commercial use of the instrument. At the end of Q3, the company had placed 49 instruments with customers under commercial agreements versus 46 instruments at the end of Q2.

Roka's net loss in the quarter grew to $9.5 million, or $5.39 per share, from $8.5 million, or $4.91 per share, in the third quarter of 2015. According to the company, deemed dividends recorded in connection with issuance of preferred shares in the third quarter had a $1.9 million, or $1.07 per share, impact on the net loss.

R&D spending in the quarter fell to $1.6 million from $2.1 million, while SG&A costs dipped down to $4.5 million from $4.9 million.

At the end of the third quarter, Roka had cash and cash equivalents totaling approximately $9 million.

During early morning trading on the Nasdaq Tuesday, shares of Roka were down almost 1 percent at $4.48.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.